MoonLake Analyst Price Targets - Benzinga

MoonLake Immunotherapeutics

MLTXNASDAQ

Trade with Public

Trade with Public

$12.52

-0.05-0.4%

마지막 업데이트: Oct 29, 5:50 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 주식 보고서

MoonLake Analyst Price Targets - Benzinga

MoonLake Analyst Price Targets

Wall Street analyst price targets and consensus rating for MoonLake (MLTX).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

12Buy

1Hold

2Sell

Consensus RatingBuy# Analysts15Avg. Consensus PT$39Upside to Avg. PT+208.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$50
Aug 13, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$45→$50
Jul 20, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
Jul 1, 2026	Leerink Partners	Thomas Smith	PT Raise	Outperform	$24→$29
Jun 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$30
Jun 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
May 12, 2026	Needham	Serge Belanger	PT Raise	Buy	$25→$30
May 11, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$45
Mar 30, 2026	BTIG	Julian Harrison	Maintained	Buy	$30
Mar 23, 2026	Wolfe Research	Andy Chen	Upgrade	Underperform→Outperform	$12→$24
Mar 19, 2026	Rothschild & Co	Qize Ding	Upgrade	Neutral→Buy	$12→$40
Mar 11, 2026	Clear Street	Kaveri Pohlman	PT Raise	Buy	$45→$70
Mar 2, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$12→$13
Mar 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$32→$40
Feb 26, 2026	Needham	Serge Belanger	Maintained	Buy	$25
Feb 24, 2026	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$30→$35
Feb 23, 2026	BTIG	Julian Harrison	PT Raise	Buy	$24→$30
Feb 23, 2026	Needham	Serge Belanger	PT Raise	Buy	$20→$25
Feb 20, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$10→$12
Feb 9, 2026	BTIG	Julian Harrison	Maintained	Buy	$24

Analyst Ratings News

What's Going On with MoonLake Immunotherapeutics Stock on Thursday?

MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.

Vandana Singh

PRO
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $50 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $50 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the price target from $45 to $50.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $45 price target.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29

Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ:MLTX) with a Outperform and raises the price target from $24 to $29.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target

BTIG analyst Julian Harrison reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $30 price target.

Benzinga Newsdesk